Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05476562 · ClinicalTrials.gov registry record
Study Conducted Among Patients With CML
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 3,234
- Enrollment target
NCT05476562: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05476562 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 3,234 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05476562 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 3,234 participants
- Enrollment target
Study Summary
Retrospective, non-interventional observational cohort study conducted among patients with CML.
Primary Outcome
Number of patients across all lines of therapy were reported to evaluate treatment sequences among the patients.
Interventions
- OTHER Tyrosine Kinase Inhibitors (TKIs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,234 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2021-10-15 |
What the finished NCT05476562 record still lists
NCT05476562 is an observational study that tracks outcomes without assigning an intervention. Its 3,234 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Tyrosine Kinase Inhibitors (TKIs) is the first listed.
NCT05476562 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05476562 about?
NCT05476562 is a clinical study titled "Study Conducted Among Patients With CML". Retrospective, non-interventional observational cohort study conducted among patients with CML.
What is the current status of trial NCT05476562?
This trial is currently completed. The enrollment target is 3,234 participants. The study started on 2021-03-08. Estimated completion is 2021-10-15.
What interventions are being tested in trial NCT05476562?
The interventions under investigation include: Tyrosine Kinase Inhibitors (TKIs) (OTHER).
Who is sponsoring clinical trial NCT05476562?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06953375 · 3,250 participants · NA
Implementation of Neuromuscular Electrical Stimulation After Total Knee Arthroplasty
- NCT06587529 · 3,218 participants · NA
Rigorous Evaluation of the READY to Stand Curriculum to Prevent the Commercial Sexual Exploitation of Children
- NCT06760507 · 3,209 participants · NA
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
- NCT04077762 · 3,266 participants · NA
Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI